CsA is commonly used after haematological SCT (HSCT) as GVHD prophylaxis. In solid organ transplantation, area under the blood concentration vs time curve (AUC) correlates with clinical outcome. However, in HSCT, it has not been determined whether the AUC is superior to trough level monitoring to optimize clinical efficacy of CsA therapy. Therefore, the aim of this study was to investigate the relationships between CsA trough levels and/or AUC early after HSCT with clinical outcome. A total of 91 children (1.1-17.3 years) were treated consecutively with HSCT for a haematological malignancy. CsA trough levels were obtained and were used to estimate the AUC, retrospectively, with a NONMEM (Non-Linear Mixed Effects Modelling) method. Subsequently, these exposure parameters were correlated to the occurrence of acute GVHD, relapse risk (RR) and OS. Low CsA trough levels were found to correlate with the occurrence of acute GVHD. In addition, a CsA AUC over 3000 mcg h/l in AML patients was associated with a higher RR and a reduced OS. This was not the case for ALL patients. Thus, monitoring CsA exposure early after HSCT and adjusting the CsA dose to a predefined target trough level and AUC may provide a tool to influence GVHD/GVL balance.
Introduction
CsA is the most extensively used drug to prevent acute GVHD after allogeneic haematopoietic SCT (HSCT) . 1 Yet, the optimal therapeutic approach for CsA to prevent acute GVHD is not determined, as reflected by treatment differences worldwide. 2 The clinical use of CsA is complicated by considerable intra-patient and inter-patient variability in pharmacokinetics (PKs) in combination with a relatively small therapeutic window. 3 For this reason, it is important to monitor the concentration of CsA in each individual, which generally relies on trough level measurements. However, trough levels correlate poorly with the area under the blood concentration vs time curve (AUC). 4 Furthermore, in solid organ transplantation, systemic exposure to CsA, as measured by the AUC, has been shown to correlate well with clinical outcome. 5, 6 In HSCT, however, it is not clear whether the AUC is superior to trough level monitoring to achieve optimal clinical effect of CsA therapy. 7 Therefore, the aim of this retrospective study was to relate CsA trough levels and estimated CsA AUCs during the early post-HSCT period with clinical outcome. Specifically, the relationship of CsA exposure with the occurrence of acute GVHD and relapse of haematological malignancy was studied.
Patients and methods

Patients
A total of 145 children, aged 1-17 years, who received a HSCT in the paediatric stem cell transplantation unit of the Leiden University Medical Centre between July 1989 and July 2007 met the inclusion criteria for this study. These criteria were an allogeneic HSCT with a matched (10/10 alleles) sibling donor or matched (X9/10 alleles) unrelated donor (UD) for a haematological malignancy, body weight between 10 and 60 kg, conventional GVHD prophylaxis consisting of CsA in combination with a short course of MTX (as described later) and CsA blood level monitoring. CsA trough levels higher than 800 mcg/l (4 þ 2 s.d. from the geometric mean), without any clinical consequence or intervention, were considered to be caused by erroneous blood sampling and were excluded from the analysis. Excluded from this study were seven patients who received more than one stem cell graft, as were another 13 patients from whom the exact CsA dosing scheme could not be retrieved.
Data on all remaining 125 patients were used for PK modelling (See the section Population PK analysis for AUC estimation). However, 25 patients did not provide evaluable trough levels during the second week after HSCT. Furthermore, in three ALL and six AML patients, CsA was tapered after 30 days and discontinued shortly thereafter because of inclusion in a prospective study on immunomodulation to prevent leukaemia relapse. Therefore, the number of evaluable cases became 91.
A total of 62 children were transplanted with a graft from a matched-sibling donor and 29 received stem cells from an UD. Patient characteristics are described in Table 1 . The stem cell source was BM in all patients, except for PBSCs in six UD-HSCT and cord blood stem cells in two matched-sibling donor HSCT. All patients were nursed in strict protective isolation using positive-pressure laminar airflow cubicles or rooms, and received total gut decontamination with non-absorbable antimicrobials to suppress the potentially pathogenic intestinal microflora; 8 before discharge, they were re-contaminated with strictly anaerobic faecal flora plus Biogarde (Cargill Texturizing Solutions Deutschland GmbH and Co KG, Hamburg, Germany). All blood products for infusion were leukocytedepleted and irradiated to a dose of 25 Gy. All patients included were engrafted. Mean day of engraftment (after transformation), defined as the first day on which blood granulocyte counts rose to 0.5 Â 10 9 /l (for two consecutive determinations), was day 24 after SCT (median: 22 days; range: 10-64 days).
GVHD prophylaxis and treatment GVHD prophylaxis included CsA in combination with a short course of MTX. Short-course MTX was given at a dose of 10 mg/m 2 i.v. at days þ 1, þ 3 and þ 6 (and in some patients, þ 11), and was combined with a 2-h infusion of CsA (2 mg/kg/day, i.v.) divided over two doses, starting from 1 to 3 days before infusion of the graft. If considered necessary by the treating physician, dose adjustments were made on the basis of trough level measurements. The route of administration of CsA was changed from a twice-daily i.v. to a twice-daily oral regimen after haematological engraftment, and in case oral medication was well tolerated, from 3 weeks post-SCT onwards. At the time of conversion, the dose of CsA was tripled in view of the difference in bioavailability of oral CsA. CsA was usually continued for 180 days, tapered thereafter and finally stopped. Acute and chronic GVHD were diagnosed by clinical manifestation and graded according to standard criteria. 9 Acute GVHD was treated with methylprednisolone (2 mg/kg/day i.v.), followed by tapering on clinical improvement; exceptionally, other drugs were used, for example, ATG, anti-CD52 Abs and thalidomide. Chronic GVHD was further characterized according to Shulman et al.
10
CsA concentration measurements During the whole period of CsA use, CsA trough levels were determined once weekly in whole blood (EDTA) by using the routine methodology of the laboratory for Clinical Pharmacy and Toxicology of the LUMC. Before 2001, CsA concentrations were measured by RIA based on MoAb concentrations (RIA, Incstar Corp., Stillwater, MN, USA), later by fluorescence polarization immunoassay using AxSYM analyzer according to manufacturer's instructions (Abbott Laboratories, Abbott Park, IL, USA). The geometric mean of the CsA blood concentration measured before and after change in analytical method was 100 and 120 mg/l, respectively (P ¼ 0.18). The lower limit of quantification was 15 mg/l.
From the patients who were included, the CsA trough level measurements from the early post-SCT period (day þ 7 through to þ 14) were retrieved. In a few patients, more than one trough level measurement was available during the second week after SCT. In these cases, selection of the lowest trough level and estimated AUC was applied as a reflection of low exposure under treatment.
Population PK analysis for AUC estimation A PK model, which was developed and described previously, 11 was updated with the data obtained for this study using Non-Linear Mixed Effects Modelling (NON-MEM, version VI release 1.2, Icon Development Solutions, Ellicott City, MD, USA). 12 Modelling results were analyzed using the statistical software package S-Plus for Windows (version 6.2 Professional, Insightful Corp., Seattle, USA). First-order conditional estimation with interaction was used throughout the modelling process. A convergence criterion of three significant digits in the parameter estimates was used. For model comparisons, the minimum value of the objective function obtained, defined as minus twice the log-likelihood, was used. The modelling process was guided by statistical and visual checks (that is, diagnostic 'goodness-of-fit' plots). A model parameter was retained in the model when including this parameter in the model resulted in a decrease of 6.63 points in the minimum value of the objective function. The previously described model, built on 17 individuals (17 full 12-h profiles), was updated with a database consisting of 125 individuals (669 trough level measurements). The combined data set revealed two relationships that had to be described to obtain an unbiased model for parameter estimations. First, an allometric relationship between patients' body weight and CsA clearance as well as central volume of distribution was incorporated in the model by means of PK ¼ TVPK Â (BW/meanBW) exp , with PK as the PK parameter, TVPK as the PK parameter for the typical patient and BW as a term for body weight. Exp refers to the exponent, typically 0.75 for clearance and 1 for volume of distribution. 13 Second, a time-dependent linear relationship for clearance was identified with a decreasing clearance from the moment of SCT up to 3 weeks (500 h) post-SCT, described in terms of CL ¼ TVCL Â (1À0.000918 Â (time post transplantationÀ500)), with TVCL used for the typical CsA clearance of the SCT patient. CsA clearance was up to 30% higher during the first 3 weeks post-SCT compared with the stable period thereafter. These adjustments resulted in a model that adequately described the entire data set. Consequently, the model obtained was used to derive CsA CL estimates for every patient on the basis of his/her collected trough levels. These so-called individual empirical Bayes estimates for clearance were used to calculate the AUC using the formula AUC ¼ F Â Dose/CL, with F defined as bioavailability.
Statistical analysis
Cumulative incidence curves were used in a competing risks setting, with death being treated as a competing event to calculate probabilities of acute GVHD and relapse. Confidence intervals were obtained from s.e. estimates of the Kaplan-Meier curves. Univariate and multivariate analyses of CsA PK parameters and patient characteristics on outcome (OS, relapse risk (RR) and TRM) were assessed using the Cox proportional hazards model. The starting point of evaluation of outcome was set at 30 days after SCT, as a consequence of the exclusion of the subset of patients with early tapering (at 30 days after SCT) of GVHD prophylaxis. The evaluation cutoff of CsA trough levels (100 mcg/l) and CsA AUC (3000 mcg h/l) was chosen close to the median. Time of SCT, donor type, time to engraftment and acute GVHD were added as covariates to the analysis. All statistical analyses were performed with the SPSS-16.0 statistical package (SPSS Inc, Chicago, IL, USA). P-values o0.05 were considered as statistically significant. The evaluation cutoff date was 1 January 2008.
Results
Acute GVHD
For children undergoing an allogeneic SCT with a matched-sibling donor (n ¼ 62), the incidence of acute GVHD was 6%, all grade I (n ¼ 4), whereas the incidence of acute GVHD in UD-SCT (n ¼ 29) seemed to be 24% (n ¼ 7). Five recipients of an UD graft experienced a GVHD grade II or higher (Table 1) . Lower CsA trough levels during the early post-SCT period were associated with a higher risk of acute GVHD. Besides the low CsA trough level (hazard decreases for every additional 10 mg/l CsA trough blood concentration), receiving a graft from an UD also was an independent prognostic factor for the development of acute GVHD (Table 2 ). Interestingly, no correlation was observed between CsA AUC and the incidence of acute GVHD. Owing to the low occurrence of acute GVHD in our patient population, we were not able to perform a sub-analysis of patients with acute GVHD grade 0 and I vs grade II or more. However, in our patients, the value of the CsA trough levels and AUCs did not correlate with the severity of the acute GVHD.
Relapse and survival
To determine the relationship between CsA trough levels or AUC and clinical outcome in children with an allogeneic SCT for a haematological malignancy, we evaluated OS, RR and TRM. Overall, the 5-year probability for OS was 60% (95% CI: 50-70%), for RR 38% (95% CI: 28-48%) and for TRM 8% (95% CI: 0-15%). For children with ALL and AML, the 5-year probability of OS was 48 and 57%, respectively, and the 5-year probability of relapse was 58 and 39%, respectively (NS). Tables 3 and 4 show the clinical relevance of CsA trough level and AUC value during the second week after SCT as markers for clinical outcome. Although CsA trough levels were not related to OS or RR (Table 3) , CsA AUC did show a relationship with clinical outcome. AUC values below 3000 mcg h/l were significantly related to higher survival rates and a decreased risk of relapse for patients diagnosed with AML. In contrast, this is not the case for patients with ALL. Figure 1 displays a Kaplan-Meier curve, displaying the outcome of patients with AML according to CsA AUC, showing OS, disease-free survival, TRM and relapse in one graph.
A multivariate Cox regression analysis was performed to investigate the effect on outcome of the following covariates: time of SCT, donor type, time to engraftment and occurrence of acute GVHD. None of these covariates had a significant influence on the outcome parameters in our study population, either in all patients together or in the subgroup of AML patients.
Discussion
To date, the optimal therapeutic approach for CsA therapy as GVHD prophylaxis after HSCT remains unclear in terms of dose, as well as monitoring strategy. 2 The benefit of adequate GVHD prophylaxis using CsA and MTX has been evaluated mainly using trough levels. Several investigators have recognized CsA exposure in the early post transplantation period as a risk factor for the development of acute GVHD. [14] [15] [16] [17] [18] In children, after HSCT, a CsA trough level lower than o85 mcg/l during the first 2 weeks post transplantation was associated with severe acute GVHD. 15 Using trough levels as a reflection of CsA exposure has the advantage that it is practical. However, the usefulness of dose adjustments based on CsA trough levels continues to be controversial. It has been argued that the CsA trough level relates poorly to the AUC. 4 In addition, it has been described that the maximal pharmacodynamic response, as measured by inhibition of calcineurin activity, coincides with the peak concentration B2 h after dose intake. 19 This indicates that monitoring the AUC or a concentration 2 h after CsA dose intake (C2) could be a better indicator of drug exposure than trough levels. In fact, a study in solid organ transplantation shows a relationship between C2 and graft rejection. 20 In HSCT, however, C2 concentrations did not show any correlation with acute GVHD in adults. 21 To further complicate CsA therapy after HSCT, it has been suggested that a high CsA dose is related to relapse of original disease. 22 Although this implicates a relationship between dosage and actual systemic exposure, it is known Table 3 Prognostic impact of CsA exposure (trough level4100 mcg/l vs o100 mcg/l) during the early post-SCT period on OS, RR and TRM in all 91 SCT patients and those transplanted for ALL and AML separately Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio; RR ¼ relapse risk.
Table 4
Prognostic impact of CsA exposure (AUC43000 mcg h/l vs AUC o3000 mcg h/l) during the early post-SCT period on OS, RR and TRM in all 91 SCT patients and those transplanted for ALL and AML separately that the inter-patient variability of systemic exposure, as reflected by CsA trough level and AUC and dosage, is high. This is because of the fact that the systemic exposure, besides the dose, depends on clearance. Drug clearance could vary between individuals because of many factors, such as demographic factors (that is, body weight), drug interactions, genetic polymorphisms and time after SCT. When taking this into account, an optimal therapeutic drug monitoring approach becomes mandatory to control the balance between acute GVHD and relapse of disease. Therefore, the aim of this study was to identify a relationship between a PK parameter and clinical outcome in terms of acute GVHD and relapse of disease. Ultimately, this study should indicate whether the use of AUC would potentially add to therapy outcome. Therefore, in this study, CsA trough levels were obtained from 125 children transplanted for a haematological malignancy. These trough levels were used to estimate the AUC with a population PK model that has been described previously, 11 but was improved in this study. The model obtained allows prediction of the clearance and AUC of an individual patient at a certain moment, given the trough level, dosage, time after SCT, body weight and age. We chose to evaluate the CsA exposure during the second week after HSCT to omit the acute toxicities of the HSCT, and thus allow some time to reach a pharmacological steady state. Furthermore, we felt that the intensity of immunosuppression during this period preceding engraftment of haematopoietic precursor cells could potentially have a role in the development of (subclinical) acute GVHD and a GVL effect.
In accordance with reports from others, [14] [15] [16] [17] [18] we observed a relationship between CsA trough levels and acute GVHD. However, the AUC did not show any correlation with occurrence of acute GVHD. This is in line with a study from Martin et al., 15 which described lower CsA trough levels in children who developed grade II-IV acute GVHD than in those developing no GVHD or only grade I, in contrast with the peak blood concentration and AUC which were comparable in both groups. Adequate GVHD prophylaxis may perhaps be more related to trough level than to other pharmacological measures of exposure, indicating the need for a sufficiently high blood trough concentration rather than the need for adequate total exposure. Despite these arguments, one would still have expected to find a relationship between AUC and acute GVHD. The reason for this absence could be because of the low incidence of acute GVHD in our patient population and/or biases in the AUC estimation. The potential error in the estimations was calculated and found to be B20% in the estimated AUC when assessed on basis of the trough levels in this study. Inclusion of more blood concentration measurements from time points after CsA dose intake might have further improved AUC estimation.
Acute GVHD contributes to both early and late mortality after HSCT, whereas lower relapse rates have been found in leukaemia patients who develop acute or chronic GVHD. This so-called GVL effect, probably mediated by donor alloreactive T cells and associated with the occurrence of acute GVHD, is an important contribution to the control of leukaemia. Its effect is considerably less for cases with acute leukaemia than for cases with CML. 23 Furthermore, lymphoid leukaemias seem less sensitive to donor lymphocyte infusions than does leukaemia from myeloid origin, 24 which is possibly due to their inability to act as APC, and also their potential to induce tolerance may be involved. 25 Locatelli et al. 22 showed that children with acute leukaemia (47 children with ALL and 12 children with AML) receiving CsA at a dose of 1 mg/kg/ day had a significantly lower risk of relapse as compared with those who received CsA at a dose of 3 mg/kg/day, probably due to increased GVL effect.
Our study shows that low systemic exposure to CsA (BAUC) during the early post transplant period was significantly associated with lower RR and higher OS, independent of development of acute GVHD, in children with AML. This was not the case for the ALL patients in our study, possibly because they are less prone to benefit from the GVL effect. The results of this study indicate that an AUC not higher than 3000 mcg h/l, particularly in AML patients, should be used to optimize clinical outcome. We therefore suggest monitoring the AUC weekly in the first weeks after HSCT, and propose a target-AUC between 2500 and 3000 mcg h/l to maximize the GVL effect. For adequate GVHD prophylaxis, a target trough level of 100 mcg/l would be reasonable. However, the risk of acute GVHD and relapse needs to be weighed against each other for each individual patient in the context of their specific HSCT. As it is inconvenient for the patient and the hospital staff to obtain sufficient samples to calculate the full AUC 0À12 h during twice-daily dosing, a limited sampling strategy 11 could be used instead. Compartmental population PK modelling with Bayesian estimation offers several advantages especially in the paediatric setting. The model is flexible, does not depend on exact blood sampling time points, enables interpretation of sets with missing data and can generally use data from children being given the drug therapeutically. It is therefore useful in clinical practice. Consequently, by using the individual patient covariates and the information obtained from an ealier population analysis, one can estimate individual PK parameters 26 or determine the dose that achieves a target concentration in the individual patient, 27 allowing further optimization of the intensity of immunosuppression.
The results of this study indicate that a close correlation of AUC with outcome exists and stresses the importance of CsA drug monitoring in SCT recipients to minimize GVHD and maximize GVL effect. The preservation of a GVL effect (especially for AML) by careful monitoring immunosuppression may further improve the outcome after SCT of children with high-risk acute leukaemia.
